Lanreotide vs Navepegritide
Overview
Lanreotide is primarily a hormonal peptide, while Navepegritide is used for bone & joint.
This page compares Lanreotide and Navepegritide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Lanreotide | Navepegritide | |
|---|---|---|
| Category | Hormonal | Bone & Joint |
| Regulatory status (US) | FDA approved | FDA approved |
| Typical dosage | 60-120 mg | — |
| Frequency | every 4 weeks | — |
| Reported benefits | suppression of excess growth hormone and IGF-1 in acromegaly, improved progression-free survival in GEP-NETs, reduction of carcinoid syndrome symptoms, inhibition of multiple GI and pancreatic hormones | — |
| Reported side effects | diarrhea, cholelithiasis, abdominal pain, hyperglycemia, bradycardia, injection site reactions, nausea, hypertension, headache, thyroid function decreases | — |
Key differences
Primary use. Lanreotide is categorised under Hormonal, while Navepegritide falls under Bone & Joint. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Lanreotide: FDA-approved. Navepegritide: FDA-approved.
Dosing. Lanreotide is typically dosed at 60-120 mg (every 4 weeks). Typical dosing for Navepegritide is not catalogued.
Can you stack them?
Some protocols combine peptides, but stacking Lanreotide and Navepegritide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Lanreotide and Navepegritide?
- Lanreotide is primarily a hormonal peptide, while Navepegritide is used for bone & joint. Lanreotide is FDA-approved for one or more indications, whereas Navepegritide is FDA-approved for one or more indications.
- What is Lanreotide used for?
- FDA-approved long-acting somatostatin analog for acromegaly, GEP-NETs, and carcinoid syndrome.
- What is Navepegritide used for?
- PEGylated CNP analog for achondroplasia. FDA approved February 27, 2026.
- Can you take Lanreotide and Navepegritide together?
- Some users combine peptides within a single protocol, but stacking Lanreotide and Navepegritide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Lanreotide or Navepegritide FDA-approved?
- Lanreotide is FDA-approved for one or more indications. Navepegritide is FDA-approved for one or more indications.
Read the full articles
- Lanreotide — full monograph: mechanism, research, dosing & references
- Navepegritide — full monograph: mechanism, research, dosing & references